Current status of cord blood transplantation in China

作     者：CHEN Yu-hong LIU Kai-yan 

作者机构：Peking University Institute of Hematology People's Hospital BeijingKey Laboratory of Hematopoietic Stem Cell Transplantation Beijing100044 China 

出 版 物：《Chinese Medical Journal》 (中华医学杂志（英文版）)

年 卷 期：2013年第126卷第23期

页      面：4594-4596页

核心收录：

学科分类：0710[理学-生物学] 071010[理学-生物化学与分子生物学] 1002[医学-临床医学] 081704[工学-应用化学] 07[理学] 08[工学] 0817[工学-化学工程与技术] 071009[理学-细胞生物学] 09[农学] 0901[农学-作物学] 090102[农学-作物遗传育种] 

主　　题：blood transplantation malignant 

摘      要：In 1988, Gluckman performed the first cord blood transplant for a 5 year old boy with Fanconi anemia using a cord blood unit from the patient＇s unaffected sister,l Patient remains alive and disease free for 24 years. Since then, extensive researches have established the safety and efficacy of umbilical cord blood transplantation （CBT） in both children and adults with a variety of malignant and non-malignant diseases. As of 2011, more than 25 000 CBTs have been performed. Compared with the unrelated bone marrow （UBM） or peripheral blood stem cells （UPBSC）, unrelated cord blood （UCB） has many theoretical and clinical advantages： （1） non-invasive and easy procurement, with little risk to the mother or newborn; （2） expands donor pool for minorities targeted;